Cited by 808Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis MechanismsAtrial Fibrillation Management and Outcomes

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism

Open access

Ridker, Paul M, Goldhaber, Samuel Z., Danielson, Ellie, Rosenberg, Yves, Eby, Charles S., Deitcher, Steven R., Cushman, Mary, Moll, Stephan, Kessler, Craig M., Elliott, C. Gregory, Paulson, Rolf, Wong, Turnly, Bauer, Kenneth A., Schwartz, Bruce A., Miletich, Joseph P., Bounameaux, Henri, Glynn, Robert J.·2003·New England Journal of Medicine

DOI 10.1056/nejmoa035029

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Standard therapy to prevent recurrent venous thromboembolism includes 3 to 12 months of treatment with full-dose warfarin with a target international normalized ratio (INR) between 2.0 and 3.0. However, for long-term management, no therapeutic agent has shown an acceptable benefit-to-risk ratio. METHODS: Patients with idiopathic venous thromboembolism who had received full-dose anticoagulation therapy for a median of 6.5 months were randomly assigned to placebo or low-intensity warfarin (target INR, 1.5 to 2.0). Participants were followed for recurrent venous thromboembolism, major hemorrhage, and death. RESULTS: The trial was terminated early after 508 patients had undergone randomization and had been followed for up to 4.3 years (mean, 2.1). Of 253 patients assigned to placebo, 37 had recurrent venous thromboembolism (7.2 per 100 person-years), as compared with 14 of 255 patients assigned to low-intensity warfarin (2.6 per 100 person-years), a risk reduction of 64 percent (hazard ratio, 0.36 [95 percent confidence interval, 0.19 to 0.67]; P<0.001). Risk reductions were similar for all subgroups, including those with and those without inherited thrombophilia. Major hemorrhage occurred in two patients assigned to placebo and five assigned to low-intensity warfarin (P=0.25). Eight patients in the placebo group and four in the group assigned to low-intensity warfarin died (P=0.26). Low-intensity warfarin was thus associated with a 48 percent reduction in the composite end point of recurrent venous thromboembolism, major hemorrhage, or death. According to per-protocol and as-treated analyses, the reduction in the risk of recurrent venous thromboembolism was between 76 and 81 percent. CONCLUSIONS: Long-term, low-intensity warfarin therapy is a highly effective method of preventing recurrent venous thromboembolism.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa035029

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,769
A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
Poort, S., Rosendaal, F. R., Reitsma, P. H., & Bertina, R. M. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,045
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,094
Resistance to Activated Protein C as a Basis for Venous Thrombosis
Svensson, P. J., & Dahlbäck, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199402243300801 · Cited by 1,127
A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism
Kearon, C., Gent, M., Hirsh, J., Weitz, J. I., Kovacs, M. J., Anderson, D. R., Turpie, A. G. G., Green, D., Ginsberg, J. S., Wells, P. S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,057
Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men
Ridker, P. M., Hennekens, C. H., Lindpaintner, K., Stampfer, M. J., Eisenberg, P. R., & Miletich, J. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321403 · Cited by 1,031
Self-citation
A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism
Schulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Very Low Doses of Warfarin Can Prevent Thrombosis in Central Venous Catheters
Bern, M. M., Lokich, J. J., Wallach, S. R., Bothe, A., Benotti, P. N., Arkin, C. F., Greco, F. A., Huberman, M., & Moore, C. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-423 · Cited by 787

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 2

Kearon C, 2002, Blood, 100, 150a
Eriksson H, 2002, Blood, 100, 81a

Sorted by citations

Items 301–400 of 807

Inherited Thrombophilia
Phillippe, H. M., Hornsby, L. B., Eudaley, S. T., Armstrong, E. M., & Bellone, J. M. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014530390 · Cited by 23
The treatment of venous thromboembolism in special populations
Rondina, M. T., Pendleton, R. C., Wheeler, M., & Rodgers, G. M. (2006) · Thrombosis Research · doi:10.1016/j.thromres.2006.05.015 · Cited by 21
“In contrast to the conclusions of these trials [71— 73], the most recent recommendations of the American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy regarding the duration of OAC therapy in patients with inherited thrombophilia bsuggest indefinite therapy as for patients with idio…”
BackgroundResultInfluential
Prevention of Recurrent Idiopathic Venous Thromboembolism
Goldhaber, S. Z. (2004) · Circulation · doi:10.1161/01.cir.0000150641.65000.f2 · Cited by 22
Self-citation
Therapeutic Potential of Oral Factor Xa Inhibitors
Hylek, E. M. (2010) · New England Journal of Medicine · doi:10.1056/nejme1012149 · Cited by 22
Inherited thrombophilia and life‐time risk of venous thromboembolism: is the burden reducible?
Stefano, V. D. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00863.x · Cited by 22
Can I Stop the Warfarin? A Review of the Risks and Benefits of Discontinuing Anticoagulation
Spiess, J. L. (2009) · Journal of Palliative Medicine · doi:10.1089/jpm.2008.0164 · Cited by 20
Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation
Yang, J., Gao, L., Zhang, Y., Wang, H., Lu, C., Zhao, Y., Xu, Q., Xu, B., Zhang, Y., & Yin, T. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-05-0362 · Cited by 21
“The effectiveness and safety of low-intensity warfarin anticoagulation were also confirmed in the preventing of recurrent venous thromboembolism (VTE) (18).”
Background
Venous Thromboembolism Overview
Battinelli, E. M., Murphy, D. L., & Connors, J. M. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.010 · Cited by 23
Guidelines for the Diagnosis, Treatment, and Follow up of Pulmonary Embolism
Uresandi, F., Blanquer, J., Conget, F., de Gregorio, M. Á., Lobo, J. L., Otero, R., Rodríguez, E. P., Monréal, M., & Morales, P. (2004) · Archivos de Bronconeumología · doi:10.1016/s1579-2129(06)60379-0 · Cited by 21
Chronic Thromboembolic Pulmonary Hypertension-Management Strategies and Outcomes
Ranka, S., Mohananey, D., Agarwal, N., Verma, B. R., Villablanca, P., Mewhort, H. E., & Ramakrishna, H. (2019) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2019.11.019 · Cited by 22
Exploring Opportunities for Primary Prevention of Unprovoked Venous Thromboembolism: Ready for Prime Time?
Folsom, A. R., & Cushman, M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.019395 · Cited by 21
Self-citation
Oral anticoagulant treatment – Evaluating the knowledge of patients admitted in physical medicine and rehabilitation units
Janoly-Duménil, A., Bourne, C., Loiseau, K., Luauté, J., Sancho, P. O., Ciancia, S., Caillet, F., Boisson, D., Rioufol, C., Plauchu, M. M., et al. (2011) · Annals of Physical and Rehabilitation Medicine · doi:10.1016/j.rehab.2011.02.007 · Cited by 22
Is Venous Thromboembolism a Chronic Inflammatory Disease?
Piazza, G., & Ridker, P. M. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.234088 · Cited by 21
Self-citation
Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen—Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study
Fiedler, K. A., Byrne, R. A., Schulz, S., Sibbing, D., Mehilli, J., Ibrahim, T., Mæng, M., Laugwitz, K., Kastrati, A., & Sarafoff, N. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.01.005 · Cited by 22
Advanced Management of Acute Iliofemoral Deep Venous Thrombosis: Emergency Department and Beyond
Pollack, C. V. (2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2010.11.031 · Cited by 20
Toward Rapid, High-Sensitivity, Volume-Constrained Biomarker Quantification and Validation using Backscattering Interferometry
Olmsted, I. R., Hassanein, M., Kussrow, A. K., Hoeksema, M., Li, M., Massion, P. P., & Bornhop, D. J. (2014) · Analytical Chemistry · doi:10.1021/ac501355q · Cited by 20
Safety, Effectiveness, and Efficiency: A Web-Based Virtual Anticoagulation Clinic
Kelly, J. J., Sweigard, K., Shields, K., & Schneider, D. (2003) · The Joint Commission Journal on Quality and Safety · doi:10.1016/s1549-3741(03)29076-6 · Cited by 20
Comparative Efficacy and Safety of Sulodexide and Other Extended Anticoagulation Treatments for Prevention of Recurrent Venous Thromboembolism: A Bayesian Network Meta-analysis
Pompilio, G., Integlia, D., Raffetto, J. D., & Palareti, G. (2020) · TH Open · doi:10.1055/s-0040-1709731 · Cited by 21
Long-term survival of patients with a history of venous thromboembolism
Reitter, S. E., Waldhoer, T., Mayerhofer, M., Eigenbauer, E., Ay, C., Kyrle, P. A., & Pabinger, I. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1160-0 · Cited by 19
Anticoagulants in the treatment of deep vein thrombosis
Merli, G. J. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.06.006 · Cited by 20
Perioperative Anticoagulation for Patients with Mechanical Heart Valves: A Survey of Current Practice
Garcia, D. A., Ageno, W., Libby, E. N., Bibb, J., Douketis, J. D., & Crowther, M. A. (2004) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-005-0346-5 · Cited by 19
“, deep venous thrombosis and acute coronary syndromes) [7,8].”
Background
Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach
Rollins, B. M., Silva, M. A., Donovan, J. L., & Kanaan, A. O. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.06.033 · Cited by 18
Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism
Coleman, C. I., Limone, B. L., Bookhart, B. K., Mody, S. H., & Nutescu, E. A. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.02.006 · Cited by 18
Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review
van der Wall, S. J., van der Pol, L. M., Ende-Verhaar, Y. M., Cannegieter, S. C., Schulman, S., Prandoni, P., Rodger, M. A., Huisman, M. V., & Klok, F. A. (2018) · European Respiratory Review · doi:10.1183/16000617.0094-2018 · Cited by 18
“The remaining 24 articles all satisfied our predetermined methodological criteria [18-41].”
Background
Thrombophilia Testing, Recurrent Thrombosis, and Women’s Health
Piazza, G. (2014) · Circulation · doi:10.1161/circulationaha.113.007664 · Cited by 18
National Consensus on the Diagnosis, Risk Stratification and Treatment of Patients with Pulmonary Embolism
Uresandi, F., Monréal, M., García-Bragado, F., Domenech, P., Lecumberri, R., Escribano, P., Zamorano, J. L., Jiménez, S., Ruiz‐Artacho, P., Lozano, F., et al. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2013.10.008 · Cited by 18
Recurrence of venous thromboembolism in patients with recent gestational deep vein thrombosis or pulmonary embolism: Findings from the RIETE Registry
Barillari, G., Londero, A. P., Brenner, B., Nauffal, D., Muñoz-Torrero, J. F. S., del Molino, F., Moustafa, F., Madridano, O., Martín‐Martos, F., Monréal, M., et al. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.02.013 · Cited by 21
Self-citation
Persistent global hypercoagulability in long-term survivors of acute pulmonary embolism
Chow, V., Reddel, C. J., Pennings, G. J., Chung, T., Ng, A. C. C., Curnow, J. L., & Kritharides, L. (2015) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000285 · Cited by 18
Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long‐term secondary prevention of venous thromboembolism
Wåhlander, K., Eriksson, H., Lundström, T., Clason, S. B., Wall, U., Nyström, P. O., Wessman, P., Schulman, S., & THRIVE III Investigators (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.05960.x · Cited by 19
“Although the findings of the present study are largely exploratory, together with the results of other studies (Baglin et al, 2003; Ridker et al, 2003; Gallus, 2005), they do not indicate that general screening for these thrombophilic defects is of clinical value in predicting whether most patients…”
BackgroundResult
Unanswered questions in venous thromboembolism
Weitz, J. I. (2009) · Thrombosis Research · doi:10.1016/s0049-3848(09)70135-5 · Cited by 18
Prognostic Implications of Warfarin Cessation After Major Trauma
Hackam, D. G., Kopp, A., & Redelmeier, D. A. (2005) · Circulation · doi:10.1161/01.cir.0000163548.38396.e7 · Cited by 18
Duration of vitamin K antagonist therapy for venous thromboembolism: a systematic review of the literature
Streiff, M. B., Segal, J. B., Tamariz, L. J., Jenckes, M. W., Bolger, D. T., Eng, J., Krishnan, J. A., & Bass, E. B. (2006) · American Journal of Hematology · doi:10.1002/ajh.20691 · Cited by 17
Optimal management of upper extremity deep vein thrombosis: Is venous thoracic outlet syndrome underrecognized?
Illig, K. A., & Gober, L. (2021) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2021.07.011 · Cited by 17
Deep thrombosis characterization using photoacoustic imaging with intravascular light delivery
Tang, Y., Wu, H., Klippel, P., Zhang, B., Huang, H. S., Jing, Y., Jiang, X., & Yao, J. (2022) · Biomedical Engineering Letters · doi:10.1007/s13534-022-00216-0 · Cited by 19
Use of a Retrievable Vena Cava Filter with Low-intensity Anticoagulation for Prevention of Pulmonary Embolism in Patients with Cancer: An Observational Study in 106 Cases
DAMASCELLI, B., Tichà, V., Patelli, G., Lanocita, R., Morosi, C., Civelli, E. M., Tolla, G. D., Frigerio, L. F., Ciceri, E. F. M., Garbagnati, F., et al. (2011) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2011.04.015 · Cited by 17
Antipsychotic drugs and the risk of recurrent venous thromboembolism: A prospective cohort study
Mollard, L.-M., Mao, R. L., Tromeur, C., Moigne, E. L., Gouillou, M., Pan‐Petesch, B., Delluc, A., Couturaud, F., & Lacut, K. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.02.030 · Cited by 17
Extended anticoagulation and mortality in venous thromboembolism. A meta-analysis of six randomized trials
Bova, C., Bianco, A., Mascaro, V., & Nobile, C. G. A. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.01.005 · Cited by 18
Diagnosis, Prevalence, And Management Of Thromboembolism In Patients With Spinal Cord Injury
Green, D. (2003) · Journal of Spinal Cord Medicine · doi:10.1080/10790268.2003.11753701 · Cited by 16
Duration of Anticoagulation: Applying the Guidelines and Beyond
Bauer, K. A. (2010) · Hematology · doi:10.1182/asheducation-2010.1.210 · Cited by 16
Self-citation
Aspirin and recurrent venous thromboembolism
Prandoni, P., Noventa, F., & Milan, M. (2013) · Phlebology The Journal of Venous Disease · doi:10.1177/0268355512475040 · Cited by 16
Hyperhomocysteinaemia and the risk of recurrent venous thrombosis: results from the MEGA follow‐up study
Hensen, A. D. O., Lijfering, W. M., Cannegieter, S. C., Rosendaal, F. R., & Vlieg, A. V. H. (2019) · British Journal of Haematology · doi:10.1111/bjh.16075 · Cited by 18
“A disadvantage of this treatment is the risk of a major or even fatal haemorrhage (1–2% per year) (Kearon et al., 2003; Ridker et al., 2003).”
Background
ANATOMICAL AND VISUAL RESULTS OF TRANSCONJUNCTIVAL SUTURELES VITRECTOMY USING SUBCONJUNCTIVAL ANESTHESIA PERFORMED ON SELECT PATIENTS TAKING ANTICOAGULANT AND ANTIPLATELET AGENTS
Malik, A. I., Foster, R. E., Corrêa, Z. M., Petersen, M. R., Miller, D. M., & Riemann, C. D. (2012) · Retina · doi:10.1097/iae.0b013e31822f55c4 · Cited by 16
Thrombophilia
Heit, J. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00014-2 · Cited by 16
Therapy Insight: approaching endoscopy in anticoagulated patients
Makar, G. A., & Ginsberg, G. G. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0387 · Cited by 16
“2% in patients who have suffered their first idiopathic DVT”
Background
Prevention and treatment of the postthrombotic syndrome
Henke, P. K. (2010) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2010.05.070 · Cited by 16
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Middeldorp, S., Prins, M. H., & Hutten, B. A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001367.pub3 · Cited by 133
Periodontal disease as a risk factor of recurrence of venous thromboembolic disease: a prospective study
Sánchez‐Siles, M., Rosa‐Salazar, V., Salazar‐Sánchez, N., & Camacho‐Alonso, F. (2014) · Acta Odontologica Scandinavica · doi:10.3109/00016357.2014.920514 · Cited by 16
Biochemical and pharmacological evaluation of 4-hydroxychromen-2-ones bearing polar C-3 substituents as anticoagulants
Mladenović, M. P., Mihailović, M., Bogojević, D., Vuković, N. L., Sukdolak, S., Matić, S. L., Nićiforović, N., Mihailović, V. B., Mašković, P., Vrvić, M. M., et al. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.04.036 · Cited by 15
Hypercoagulability and venous thromboembolism: a review.
Mazza, J. J. (2004) · PubMed · Cited by 15
Hypercoagulable state testing and malignancy screening following venous thromboembolic events
Deitcher, S. R., & Gomes, M. P. V.-F. (2003) · Vascular Medicine · doi:10.1191/1358863x03vm461ra · Cited by 16
Self-citation
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial
Bikdeli, B., Hogan, H., Morrison, R. B., Fanikos, J. R., Campia, U., Barns, B. M., Pfeferman, M. B., Snyder, J. E., Khairani, C. D., Goldhaber, S. Z., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1646-2244 · Cited by 15
Self-citation
Contemporary management of pulmonary embolism: the answers to ten questions
Bounameaux, H. M. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02254.x · Cited by 14
Self-citation
Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients
Lutsey, P. L., Norby, F. L., Zakai, N. A., MacLehose, R. F., Chen, L. Y., Shah, S., Datta, Y. H., & Alonso, Á. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541445 · Cited by 15
Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty
Gage, B. F., Bass, A. R., Lin, H., Woller, S. C., Stevens, S. M., Al-Hammadi, N. J., Anderson, J. L., Li, J., Rodriguez, T., Miller, J. P., et al. (2019) · JAMA · doi:10.1001/jama.2019.12085 · Cited by 15
Self-citation
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin
Prandoni, P., Lensing, A. W. A., Prins, M. H., Gebel, M., Pap, A. F., Homering, M., Bauersachs, R. M., Beyer‐Westendorf, J., Bounameaux, H., Cohen, A. T., et al. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.06.009 · Cited by 14
Self-citation
NHG-Standaard Diepe veneuze trombose
Oudega, R., van Weert, H. C. P. M., Stoffers, J., Sival, P. P. E., Schure, R. I., Delemarre, J., & Eizenga, W. H. (2009) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-6614-9_2 · Cited by 14
Optimisation de l’interrogatoire dans l’évaluation du risque de maladie thromboembolique veineuse : l’étude OPTIMEV
Sevestre, M., Labarère, J., Brin, S., Carpentier, P., Constans, J., Degeilh, M., Deslandes, B., Elgrishi, I., Lanoye, P., Laroche, J.-P., et al. (2005) · Journal des Maladies Vasculaires · doi:10.1016/s0398-0499(05)88206-x · Cited by 13
Low Intensity Warfarin Anticoagulation is Safe and Effective as a Long-Term Venous Thromboembolism Prevention Strategy
Goldhaber, S. Z. (2006) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-006-5576-7 · Cited by 14
Self-citation
Warfarin for Venous Thromboembolism — Walking the Dosing Tightrope
Schafer, A. I. (2003) · New England Journal of Medicine · doi:10.1056/nejme030018 · Cited by 14
An Aspirin a Day to Keep the Clots Away
Wakefield, T. W., Andrea, T., & Henke, P. K. (2014) · Circulation · doi:10.1161/circulationaha.114.012235 · Cited by 14
“†73% to 93% of patients with unprovoked VTE. by guest on O ctober 11, 2017 http://circ.ahajournals.org/ D ow nloaded from Wakefield et al Prevention of Recurrent Venous Thromboembolism 1033 contraceptives), is taking 1 aspirin per day at the end of a full course of anticoagulation beneficial?”
BackgroundInfluential
Overestimation of benefit when clinical trials stop early: a simulation study
Liu, S., & Garrison, S. (2022) · Trials · doi:10.1186/s13063-022-06689-9 · Cited by 14
“Simulation of trial parameters The template trial we built our model on was a comparison of low-intensity warfarin versus placebo for the prevention of recurrent venous thromboembolism [6].”
Method
Bleeding Risk in Elderly Patients with Venous Thromboembolism Who Would Have Been Excluded from Anticoagulation Trials
Schenker, C., Stalder, O., Méan, M., Tritschler, T., Righini, M., Rodondi, N., & Aujesky, D. (2023) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1760365 · Cited by 13
Diretrizes sobre trombose venosa profunda da Sociedade Brasileira de Angiologia e Cirurgia Vascular
Sobreira, M. L., Marques, M. A., Paschôa, A. F., Ribeiro, A. J. A., Casella, I. B., Burihan, M. C., Matielo, M. F., Soares, R. D. A., de Araújo, W. J. B., Joviliano, E. É., et al. (2024) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.202301071 · Cited by 18
Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report
Rankin, J., Nagar, M., Crosby, J., Toomari, N., Pietras, R. J., & Ben-Zur, U. (2016) · Journal of Medical Case Reports · doi:10.1186/s13256-016-1135-9 · Cited by 13
Long-Term Risk of Major Bleeding after Discontinuing Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis
Khan, F., Rahman, A. A., Tritschler, T., Carrier, M., Kearon, C., Weitz, J. I., Schulman, S., Couturaud, F., Becattini, C., Agnelli, G., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1690-8728 · Cited by 13
“2 (18-95) ISTH (exogenous estrogen) ISTH 1 6”
Background
Chronic Thromboembolic Pulmonary Hypertension: Medical Treatment
Özsu, S., & Çınarka, H. (2013) · Pulmonary Circulation · doi:10.4103/2045-8932.114761 · Cited by 13
“[18] Long-term anticoagulant therapy was shown to reduce the risk of recurrent thromboembolism, particularly in patients with idiopathic or unprovoked pulmonary embolism.[19,20] In a small study including 10 patients with an mPAP below 30 mmHg who were receiving oral anticoagulant therapy, the functional capacity (FC)…”
Bleeding Risk and Major Adverse Events in Patients With Previous Ulcer on Oral Anticoagulation Therapy
Lee, S., Shin, D., Hwang, H.-J., Kim, J., Pak, H., Lee, M., & Joung, B. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.03.036 · Cited by 13
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension
Moriarty, J. M., Khan, S. N., Kao, S. D., & Saggar, R. (2018) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-018-2012-2 · Cited by 14
Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics
Fox, K. A. A., White, H. D., Opie, J., Gersh, B. J., & Opie, L. H. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-6158-8.50014-9 · Cited by 13
Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France
Ruivard, M., Berger, C., Achaibi, A., Campagne, C., & Philippe, P. (2003) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2003.21230.x · Cited by 13
Extended anticoagulation for unprovoked venous thromboembolism: a majority of patients should be treated
Kearon, C. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0573-x · Cited by 13
Management of Hereditary Hypercoagulable Disorders
Bockenstedt, P. L. (2006) · Hematology · doi:10.1182/asheducation-2006.1.444 · Cited by 13
d‐Dimer testing to predict recurrence risk in venous thromboembolism: looking for a useful threshold: a rebuttal
Gal, G. L., & Bounameaux, H. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00891.x · Cited by 13
Self-citation
Ximelagatran: An Oral Direct Thrombin Inhibitor
Dager, W. E., Vondracek, T. G., McIntosh, B. A., & Nutescu, E. A. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e078 · Cited by 13
Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada
Quon, P., Le, H. H., Raymond, V., Mtibaa, M., & Moshyk, A. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2016.1141780 · Cited by 12
Mortality Rate in Upper Gastrointestinal Bleeding Associated with Anti-Thrombotic Therapy Before and During Covid-19 Pandemic
Popa, P., Iordache, S., Florescu, D. N., Iovănescu, V. F., Vieru, A.-M., Barbu, V., Beznă, M. C., Alexandru, D. O., Ungureanu, B. S., & Cazacu, S. M. (2022) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s380500 · Cited by 12
“Treatment with DOACs requires no laboratory follow-up and may have fewer drug interactions; DOAC prescription increases substantially each year after 2010.(9,10) In patients with coronary heart disease, antiplatelet agents have a significant effect on reducing mortality and therefore, they need to be administered for…”
Background
An Update on the “Novel” and Direct Oral Anticoagulants, and Long-Term Anticoagulant Therapy
Djulbegovic, M., & Lee, A. I. (2018) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2018.04.010 · Cited by 12
Risk of Recurrent Venous Thromboembolism After an Initial Episode: Risk Stratification and Implications for Long-term Treatment
Agrawal, V., & Kim, E. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1111-2 · Cited by 13
Closure of patent foramen ovale in cryptogenic stroke
Blackshear, J. L. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.06.002 · Cited by 12
Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran
Harenberg, J., Jörg, I., & Weiß, C. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0076-9 · Cited by 12
Advances in the management of venous thromboembolism
Schulman, S. (2012) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2012.06.003 · Cited by 12
Duration of primary/secondary treatment to prevent recurrent venous thromboembolism: a systematic review and meta-analysis
Li, A., Khatib, R., Lopes, L. C., Aloweni, F. B. A. B., Lu, L., He, Q., Wu, J., Zhang, P., Tang, Y., Pavalagantharajah, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015371 · Cited by 11
The nurse specialist and practical issues in the care of pulmonary arterial hypertension patients
Housten-Harris, T. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01616.x · Cited by 11
Evaluating patient values and preferences for thromboprophylaxis decision making during pregnancy: a study protocol
Alonso‐Coello, P., Ebrahim, S., Guyatt, G. H., Tikkinen, K. A. O., Eckman, M. H., Neumann, I., McDonald, S. D., Akl, E. A., & Bates, S. M. (2012) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-12-40 · Cited by 10
Antithrombotic Drug Therapy in Cardiovascular Disease
Askari, A. T., & Lincoff, A. M. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-235-3 · Cited by 11
Quality Evaluation of the Management of Oral Anticoagulation Therapy (OAT): The Awareness of Treating Physicians and the Education of Patients Needs to Be Improved
Gras‐Champel, V., Voyer, A., Guillaume, N., Lematte, C., Roussel, B., Machu-Prestaux, C., Andréjak, M., & Lefrère, J. (2006) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000158339.08483.10 · Cited by 11
Synthesis and toxicological studies of in vivo anticoagulant activity of novel 3-(1-aminoethylidene)chroman-2,4-diones and 4-hydroxy-3-(1-iminoethyl)-2H-chromen-2-ones combined with a structure-based 3-D pharmacophore model
Stanković, N., Mladenović, M. P., Mihailović, M., Јovanović, J. A., Uskoković, A. S., Stanković, V., Mihailović, V. B., Stanković, J. S. K., Matić, S. L., Solujić, S., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.01.004 · Cited by 11
“Consequently, vitamin K-dependent synthesis of biologically active forms of clotting factors II (prothrombin), VII, IX, and X is temporarily blocked (Ridker et al., 2003).”
Background
Perioperative Management of Oral Anticoagulation
O'Donnell, M. J., & Kearon, C. (2006) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2005.09.008 · Cited by 11
Critical Role of Inferior Vena Caval Filter Placement After Pulmonary Embolectomy
Rosenberger, P., Shernan, S. K., Rawn, J. D., Scott, J., & Eltzschig, H. K. (2005) · Journal of Cardiac Surgery · doi:10.1111/j.1540-8191.2005.200426.x · Cited by 11
Trial Protocol: A randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study)
Tullett, J., Murray, E. T., Nichols, L., HOLDER, R. L., Lester, W., Rose, P. E., Hobbs, R. F., & Fitzmaurice, D. A. (2013) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-13-16 · Cited by 12
“Studies of extended treatment with low dose warfarin have confirmed that maximal benefit is conferred at standard therapeutic targets rather than fixed low dose regimes [11,12].”
Background
A Silent Killer—Often Preventable
Futterman, L. G., & Lemberg, L. (2004) · American Journal of Critical Care · doi:10.4037/ajcc2004.13.5.431 · Cited by 10
Long‐term low‐dose warfarin use is effective in the prevention of recurrent venous thromboembolism: no
Kovacs, M. J. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00825.x · Cited by 11
Pharmacogenetics of oral anticoagulants
Rojas, J. C., Aguilar, B., Rodrı́guez, E., & Collados, M. T. (2005) · Blood Coagulation & Fibrinolysis · doi:10.1097/01.mbc.0000174079.47248.0c · Cited by 11
Treatment of Venous Thromboembolism
Merli, G. J. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.08.004 · Cited by 11
Factor V Leiden as a Common Genetic Risk Factor for Venous Thromboembolism
Horne, M. K., & McCloskey, D. J. (2006) · Journal of Nursing Scholarship · doi:10.1111/j.1547-5069.2006.00072.x · Cited by 11
[Fifty years of clinical use of warfarin].
Quintero-González, J. A. (2010) · PubMed · Cited by 11
Different finite durations of anticoagulation and outcomes following idiopathic venous thromboembolism: a meta-analysis
Holley, A. B., King, C. S., Jackson, J. L., & Moores, L. K. (2010) · Thrombosis · doi:10.1155/2010/540386 · Cited by 10
“Two additional RCTs that enrolled patients with idiopathic VTE but met exclusion criteria, one because several patients in one arm were diagnosed with APAS at enrollment [26] and the other because one third of patients had previous VTE [27], were added back to see if their inclusion would impact our results.”
Background
Prolongation d’un traitement par antivitamine K pendant dix-huit mois versus placebo au décours d’un premier épisode d’embolie pulmonaire idiopathique traité six mois : un essai randomisé multicentrique en double aveugle. Essai « PADIS-EP »
Couturaud, F., Pernod, G., Pison, C. M., Mismetti, P., Sanchez, O., Meyer, G., Parent, F., Girard, P., Simonneau, G., Drouet, L. O., et al. (2008) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(08)74358-4 · Cited by 10
The Future of Deep Venous Thrombosis and Post-thrombotic Syndrome in 2020
Comerota, A. J. (2012) · Phlebology The Journal of Venous Disease · doi:10.1258/phleb.2011.012s08 · Cited by 10
The treatment and prevention of deep vein thrombosis in the preoperative management of patients who have neurologic diseases
Farray, D., Carman, T. L., & Fernandez, B. B. (2004) · Neurologic Clinics · doi:10.1016/j.ncl.2004.01.002 · Cited by 10

Authors: Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., Paulson, R., Wong, T., Bauer, K. A., Schwartz, B. A., Miletich, J. P., Bounameaux, H., & Glynn, R. J.
Affiliations: Brigham and Women's Hospital (US)
National Institutes of Health (US)
Washington University in St. Louis (US)
Cleveland Clinic (US)
University of Vermont (US)
University of North Carolina at Chapel Hill (US)
Georgetown University Medical Center (US)
LDS Hospital (US)
Altru Health System (US)
St. Boniface Hospital (CA)
Beth Israel Deaconess Medical Center (US)
University Hospital of Geneva (CH)
ORCID: Ridker, Paul M
Goldhaber, Samuel Z.
Rosenberg, Yves
Cushman, Mary
Moll, Stephan
Kessler, Craig M.
Elliott, C. Gregory
Bauer, Kenneth A.
Bounameaux, Henri
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2003-04-10
Volume: 348
Issue: 15
Pages: 1425-1434
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa035029
OpenAlex: W2112757583
Cited by: 808
References: 29
Citations by year: 2026: 3 · 2025: 9 · 2024: 5 · 2023: 7 · 2022: 10 · 2021: 13 · 2020: 16 · 2019: 23 · 2018: 16 · 2017: 19 · 2016: 25 · 2015: 24 · 2014: 45 · 2013: 38 · 2012: 44
FWCI: 53.42
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords: recurrent venous thromboembolism, long-term anticoagulation, idiopathic venous thromboembolism, major bleeding, inherited thrombophilia, international normalized ratio, benefit-risk balance
MeSH terms: Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Risk, Thromboembolism, Warfarin, International Normalized Ratio, Venous Thrombosis, Stroke, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks